An open pilot study assessing the benefits of quetiapine for the prevention of migraine refractory to the combination of atenolol, nortriptyline, and flunarizine

Pain Medicine

Volumn 11, Issue 1, 2010, Pages 48-52

  Krymchantowski, Abouch V ^a   Jevoux, Carla ^b   Moreira, Pedro Ferreira ^b  

^a Headache Center of Rio   (Brazil)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Migraine; Preventive treatment; Quetiapine; Refractory

Indexed keywords

ATENOLOL; FLUNARIZINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; QUETIAPINE; TRIPTAN DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFUSION; DROWSINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG USE; FEMALE; HEADACHE; HUMAN; INCREASED APPETITE; MALE; MIGRAINE; MORBIDITY; NAUSEA; PILOT STUDY; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; WEIGHT GAIN;

EID: 73949116637     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2009.00757.x     Document Type: Article

References (29)

1. Stewart WF, Schechter A, Lipton RB. Migraine heterogeneity, disability, pain intensity and attack frequency and duration. Neurology 1994, 44(4):S24-39. suppl
2. Rasmussen BK. Epidemiology of headache. Cephalalgia 1995, 15:45-68.
3. The international classification of headache disorders, 2nd edition. Cephalalgia 2004, 24(1):1-160. Headache Classification Subcommittee of the International Headache Society, suppl
4. Stewart WF, Lipton RB, Simon D. Work-related disability: Results from the American migraine study. Cephalalgia 1996, 16:231-8.
5. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med 2002, 346:257-70.
6. Welch KMA, D'Andrea G, Tepley N, Barkley G, Ramadan NM. The concept of migraine as a state of central neuronal hiperexcitability. Neurol Clin 1990, 8:817-28.
7. Gardner-Medwin AR, Bruggen NV, Williams SR, Ahier RG. Magnetic resonance imaging of propagating waves of spreading depression in the anaethetised rat. J Cereb Blood Flow Metab 1994, 14:7-11.
8. Welch KMA, Barkley GL, Tepley N. Central neurogenic mechanisms of migraine. Neurology 1993, 43:S21-25.
9. Weiller C, May A, Limmroth V. Brainstem activation in spontaneous human migraine attacks. Nat Med 1995, 1:658-60.
10. Fanciullacci M, Alessandri M, Del Rosso A. Dopamine involvement in the migraine attack. Funct Neurol 2000, 15(3):171-81. suppl
11. Holland PR, Ackerman S, Goadsby PJ. Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat. Eur J Neurosci 2006, 24(10):2825-33.
12. Goadsby PJ, Hoskin KL, Storer RJ. Adenosine (A1) receptor agonists inhibit trigeminovascular nociceptive transmission. Brain 2002, 125:1392-401.
13. Low NC, Du Fort GG, Cervantes P. Prevalence, clinical correlates, and treatment of migraine in bipolar disorder. Headache 2003, 43:940-9.
14. Silberstein SD, Peres MF, Hopkins MM. Olanzapine in the treatment of refractory migraine and chronic daily headache. Headache 2002, 42(6):515-8.
15. LaPorta LD. Relief from migraine headache with aripiprazole treatment. Headache 2007, 47(6):922-6.
16. Dodick DW. Acute and prophylactic management of migraine. Clin Cornerstone 2001, 4:36-52.
17. Bigal ME, Lipton RB, Krymchantowski AV. The medical management of migraine. Am J Ther 2004, 11(2):130-40.
18. Krymchantowski AV. Polytherapy in migraine and chronic migraine prevention. Clinical experience with the combination of a beta-blocker plus a tricyclic antidepressant plus a calcium channel blocker. Headache 2004, 44:499-500. Abstract
19. Tfelt-Hansen P, Rolan P, Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA. adrenoceptor blocking drugs in migraine prophylaxis. The Headaches 2006, 519-28. In, eds., 3rd, edition, Philadelphia, PA, Lippincott Williams & Wilkins
20. Toda N, Tfelt-Hansen P, Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA. Calcium antagonists in migraine prophyalxis. The Headaches 2006, 539-44. In, eds., 3rd, edition, Philadelphia, PA, Lippincott Williams & Wilkins
21. Silberstein SD, Saper JR, Freitag FG, Silberstein SD, Lipton RB, Dalessio DJ. Migraine: Diagnosis and treatment. Wolff's Headache and Other Head Pain 2001, 121-246. In, eds., 7th, edition, New York, Oxford University Press
22. Tfelt-Hansen P, Welch KMA, Olesen J, Tfelt-Hansen P, Welch KMA. General principles of pharmacological treatment of migraine. The Headaches 2000, 385-9. In, eds., 2nd, edition, Philadelphia, PA, Lippincott Willians & Wilkins
23. Silberstein SD, Young WB, Mendizabal JE, Rothrock JF, Alam AS. Acute migraine treatment with droperidol: A randomized, double-blind, placebo-controlled trial. Neurology 2003, 60(2):315-21.
24. Schatzberg AF, Cole JO, Debattista C. Manual of Clinical Psychopharmacology 2002, 199-200. 4th, edition, Washington, DC, American Psychiatric Publishing
25. Brandes JL, Roberson SC, Pearlamn SH. Quetiapine for migraine prophylaxis. Headache 2002, 42:450-1. Abstract
26. Seeman P, Tallerico T. Rapid release of antipsychotic drugs from Dopamine D2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine and quetiapine. Am J Psychiatry 1999, 156:876-84.
27. Krymchantowski AV, Bigal ME. Polytherapy in the preventive and acute treatment of migraine: Fundamentals for changing the approach. Expert Rev Neurother 2006, 6(3):283-9.
28. Pascual J, Leira R, Lainez JM. Combined therapy for migraine prevention? Clinical experience with a β-blocker plus sodium valproate in 52 resistant migraine patients. Cephalalgia 2003, 23:961-2.
29. Krymchantowski AV. Refractoriness in migraine treatment: What are we talking about? Expert Rev Neurother 2005, 5(5):557-9.